Palvella Therapeutics, Inc.: capital expenditure payments
Capital expenditure payments for Palvella Therapeutics, Inc. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All Palvella Therapeutics, Inc. financial histories
What this measure means
Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.
Exact concept: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value covers an annual-duration reporting interval, shown with both start and end dates. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2013-01-01 to 2023-12-31. The SEC response was captured on 2026-09-20.
This selected history ends more than two years before capture. Do not treat its final value as a current balance or current annual result. More recent filings may use another accounting tag; inspect the filings before drawing conclusions about the company.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| 2023-01-01 | 2023-12-31 | 171,000 | USD | 2024-03-29 | 10-K · 0001437749-24-010123 |
| 2022-01-01 | 2022-12-31 | 1,041,000 | USD | 2024-03-29 | 10-K · 0001437749-24-010123 |
| 2021-01-01 | 2021-12-31 | 949,000 | USD | 2023-03-31 | 10-K · 0001437749-23-008834 |
| 2020-01-01 | 2020-12-31 | 2,726,000 | USD | 2022-03-02 | 10-K · 0001583648-22-000016 |
| 2019-01-01 | 2019-12-31 | 2,462,000 | USD | 2021-03-31 | 10-K · 0001583648-21-000005 |
| 2018-01-01 | 2018-12-31 | 1,698,000 | USD | 2020-03-13 | 10-K · 0001583648-20-000015 |
| 2017-01-01 | 2017-12-31 | 1,950,000 | USD | 2019-03-18 | 10-K · 0001583648-19-000011 |
| 2016-01-01 | 2016-12-31 | 560,000 | USD | 2018-03-15 | 10-K · 0001583648-18-000017 |
| 2015-01-01 | 2015-12-31 | 620,747 | USD | 2017-03-30 | 10-K · 0001193125-17-102052 |
| 2014-01-01 | 2014-12-31 | 267,406 | USD | 2016-03-23 | 10-K · 0001193125-16-514870 |
| 2013-07-01 | 2014-06-30 | 0 | USD | 2014-09-12 | 10-K · 0001583648-14-000010 |
| 2013-01-01 | 2013-12-31 | 49,471 | USD | 2015-03-30 | 10-K · 0001193125-15-109883 |
Related financial histories
- Palvella Therapeutics, Inc.: total assets
- Palvella Therapeutics, Inc.: total liabilities
- Palvella Therapeutics, Inc.: stockholders equity
- Palvella Therapeutics, Inc.: cash and cash equivalents
- Palvella Therapeutics, Inc.: net income or loss
- Palvella Therapeutics, Inc.: operating cash flow
- Palvella Therapeutics, Inc.: revenue
- Palvella Therapeutics, Inc.: financing cash flow
- Palvella Therapeutics, Inc.: investing cash flow
- Palvella Therapeutics, Inc.: retained earnings or deficit
- Palvella Therapeutics, Inc.: basic weighted-average shares
- Palvella Therapeutics, Inc.: diluted weighted-average shares
- Palvella Therapeutics, Inc.: basic earnings per share
- Palvella Therapeutics, Inc.: diluted earnings per share
- Palvella Therapeutics, Inc.: income tax expense or benefit
- Palvella Therapeutics, Inc.: net property, plant and equipment
- Palvella Therapeutics, Inc.: share-based compensation expense
- Palvella Therapeutics, Inc.: operating income or loss
- Palvella Therapeutics, Inc.: current assets
- Palvella Therapeutics, Inc.: current liabilities
- Palvella Therapeutics, Inc.: current accounts payable
- Palvella Therapeutics, Inc.: net current accounts receivable
- Palvella Therapeutics, Inc.: operating expenses
- Palvella Therapeutics, Inc.: research and development expense
Inspect the source
- Entity
- Palvella Therapeutics, Inc. / CIK 0001583648
- Captured
- 2026-09-20T09:22:58.497Z
- SEC response SHA-256
6b68c40c9037b15f9345bb6bb1fdc7777b1252c77cab2e34faa81275beefef40
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001583648.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))